Citi raised the firm’s price target on ArriVent Biopharma to $36 from $30 and keeps a Buy rating on the shares. The company’s Phase 1b FURTHER interim data for first-line firmonertinib monotherapy in patients with non-small cell lung cancer harboring EGFR PACC mutations is competitive against other therapies in the space, showing an “impressive” overall response rate of 63.6% at the 240mg dose, the analyst tells investors in a research note. The firm updated ArriVent’s model post the data and Q2 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVBP:
- ArriVent Biopharma price target raised to $39 from $35 at Oppenheimer
- ArriVent Biopharma price target raised to $36 from $30 at H.C. Wainwright
- ArriVent announces PoC global Phase 1b interim data for firmonertinib
- Corbus Pharmaceuticals appoints Kung to board of directors
- ArriVent Biopharma price target raised to $30 from $25 at H.C. Wainwright